Surgical Strategy for Recurrent Giant Cell Tumor in the Thoracolumbar Spine

Abstract

Objective:: Recurrent giant cell tumor (RGCT) of the spine represents a clinical challenge for surgeons, and the treatment strategy remains controversial. This study aims to describe the long-term follow-up outcomes and compare the efficacy of en bloc spondylectomy versus piecemeal spondylectomy in treating RGCT of the thoracolumbar spine.

Methods:: A total of 32 patients with RGCT of the thoracolumbar spine treated from June 2012 to June 2019 were retrospectively reviewed. A total of 15 patients received total en bloc spondylectomy (TES) with wide or marginal margin while 17 patients received total piecemeal spondylectomy (TPS) with intralesional margin. Postoperative Eastern Cooperative Oncology Group Performance Score (ECOG-PS), Frankel classification and recurrence-free survival (RFS) were evaluated after surgery. Survival curves were estimated by the Kaplan–Meier method and differences were analyzed with the log-rank test. Multivariate analysis was performed with Cox regression to identify the independent prognostic factors affecting RFS.

Results:: During a median follow-up of 41.9 ± 17.5 months, all patients with compromised neurologic functions exhibit significant improvement, with the mean ECOG-PS decreasing from 1.5 ± 1.3 to 0.13 ± 0.3 (p < 0.05). Among the 17 patients treated with TPS, eight patients developed local recurrence after a median time of 15.9 ± 6.4 months and four patients died from progressive disease. On the other hand, local recurrence were well managed with TES, since only one out of 15 patients experienced local relapse and all patients are alive with satisfied function at the latest follow-up. The median RFS for patients receiving TES and TPS are 75.0 months (95% CI: 67.5–82.5 m) and 38.3 months (95% CI: 27.3–49.3 m) respectively (p = 0.008). Multivariate analysis shows that the Ki67 index (p = 0.016), resection mode (p = 0.022), and denosumab (p = 0.039) are independent risk factors affecting RFS.

Conclusions:: TES with wide/marginal margin should be offered to patients with RGCT whenever feasible, given its long-term benefits in local control and symptom alleviation. Additionally, patients with lower Ki67 index and application of denosumab tend to have a better prognosis.

Keywords

Denosumab / En bloc spondylectomy / Giant cell tumor of bone / Spinal neoplasms

References

[1] van der Heijden L, Dijkstra PD, van de Sande MA, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014;19(5):550–561.

[2] Donthineni R, Boriani L, Ofluoglu O, Bandiera S. Metastatic behaviour of giant cell tumour of the spine. Int Orthop. 2009;33(2):497–501.

[3] Lin WH, Lan TY, Chen CY, Wu K, Yang RS. Similar local control between phenol- and ethanol-treated giant cell tumors of bone. Clin Orthop Relat Res. 2011;469(11):3200–3208.

[4] Machak GN, Snetkov AI. The impact of curettage technique on local control in giant cell tumour of bone. Int Orthop. 2021;45(3):779–789.

[5] Luksanapruksa P, Buchowski JM, Singhatanadgige W, Bumpass DB. Systematic review and meta-analysis of en bloc vertebrectomy compared with intralesional resection for giant cell tumors of the mobile spine. Global Spine J. 2016;6(8):798–803.

[6] Duan PG, Sheng YH, Deng CH, Tang BY, Yao HQ. Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report. BMC Musculoskelet Disord. 2020;21(1):105.

[7] Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–908.

[8] Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G, et al. Preoperative denosumab with curettage and cryotherapy in Giant cell tumor of bone: is there an increased risk of local recurrence? Clin Orthop Relat Res. 2018;476(9):1783–1790.

[9] Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, et al. Denosumab may increase the risk of local recurrence in patients with Giant-cell tumor of bone treated with curettage. J Bone Joint Surg Am. 2018;100(6):496–504.

[10] Chan P, Boriani S, Fourney DR, Biagini R, Dekutoski MB, Fehlings MG, et al. An assessment of the reliability of the Enneking and Weinstein-Boriani-Biagini classifications for staging of primary spinal tumors by the Spine Oncology Study Group. Spine (Phila Pa 1976). 2009;34(4):384–391.

[11] Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2001;26(3):298–306.

[12] Missenard G, Bouthors C, Fadel E, Court C. Surgical strategies for primary malignant tumors of the thoracic and lumbar spine. Orthop Traumatol Surg Res. 2020;106(1s):S53–s62.

[13] Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–120.

[14] Orguc S, Arkun R. Primary tumors of the spine. Semin Musculoskelet Radiol. 2014;18(3):280–299.

[15] Boriani S, Bandiera S, Casadei R, Boriani L, Donthineni R, Gasbarrini A, et al. Giant cell tumor of the mobile spine: a review of 49 cases. Spine (Phila Pa 1976). 2012;37(1):E37–E45.

[16] Charest-Morin R, Fisher CG, Varga PP, Gokaslan ZL, Rhines LD, Reynolds JJ, et al. En bloc resection versus intralesional surgery in the treatment of Giant cell tumor of the spine. Spine (Phila Pa 1976). 2017;42(18):1383–1390.

[17] Boriani S, Gasbarrini A, Bandiera S, Ghermandi R, Lador R. Predictors for surgical complications of en bloc resections in the spine: review of 220 cases treated by the same team. Eur Spine J. 2016;25(12):3932–3941.

[18] Boriani S, Bandiera S, Donthineni R, Amendola L, Cappuccio M, De Iure F, et al. Morbidity of en bloc resections in the spine. Eur Spine J. 2009;19(2):231–241.

[19] Boriani S, Cecchinato R, Cuzzocrea F, Bandiera S, Gambarotti M, Gasbarrini A. Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal. Eur Spine J. 2020;29(2):257–271.

[20] Jones M, Holton J, Hughes S, Czyz M. Total en bloc spondylectomy. J Spine Surg. 2018;4(3):663–665.

[21] Yokogawa N, Murakami H, Demura S, Kato S, Yoshioka K, Tsuchiya H. Incidental durotomy during total en bloc spondylectomy. Spine J. 2018;18(3):381–386.

[22] Sciubba DM, De la Garza Ramos R, Goodwin CR, et al. Total en bloc spondylectomy for locally aggressive and primary malignant tumors of the lumbar spine. Eur Spine J. 2016;25(12):4080–4087.

[23] Xu W, Li X, Huang W, Wang Y, Han S, Chen S, et al. Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center. Ann Surg Oncol. 2013;20(3):804–810.

[24] Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275–280.

[25] Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, et al. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol. 2016;69(3):240–247.

[26] Palmerini E, Staals EL, Jones LB, Donati DM, Longhi A, Randall RL. Role of (neo)adjuvant denosumab for Giant cell tumor of bone. Curr Treat Options Oncol. 2020;21(8):68.

[27] Tsukamoto S, Mavrogenis AF, Kido A, Errani C. Current concepts in the treatment of Giant cell tumors of bone. Cancers. 2021;13(15):3647.

[28] Chawla S, Blay JY, Rutkowski P, le Cesne A, Reichardt P, Gelderblom H, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719–1729.

[29] van der Heijden L, Lipplaa A, van Langevelde K, Bovée JVMG, van de Sande MAJ, Gelderblom H. Updated concepts in treatment of giant cell tumor of bone. Curr Opin Oncol. 2022;34(4):371–378.

[30] Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. 2019;139(10):1339–1349.

[31] Roeder F, Timke C, Zwicker F, Thieke C, Bischof M, Debus J, et al. Intensity modulated radiotherapy (IMRT) in benign giant cell tumors–a single institution case series and a short review of the literature. Radiat Oncol. 2010;26(5):18.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.